Skip to main content

Table 2 Summary of physical features and diagnostic symptom profile for the CFS/ME cohort investigated for cytokine and activin/follistatin variation

From: Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study

Measurement Median (range)
CFS/ME cohort Healthy control cohort
Height (cm) 165.0 (122–188) 171.5 (153–187)
Weight (kg) 60.0 (52–124) 66.0 (51–98)
BMI 22.2 (18.9–47.2) 21.9 (19.6–32.1)
Blood pressure
 Systolic (mmHg) 120.0 (102–168) 121.5 (107–140)
 Diastolic (mmHg) 80.0 (65–104) 74.0 (55–90)
 Pulse rate (bpm) 72.0 (51–102) 60.0 (43–89)
Epworth sleep scale 6.0 (0–20) 4.0 (0–15)
Canadian criteria symptoms (percentage) CFS/ME cohort
Reported by 100% of study participants Fatigue ≥6 months Post-exertional fatigue
Activity limited Stress with activity
Unrefreshing sleep Reduced concentration
Impaired thinking + speech Orthostatic intolerance
Vertigo Food intolerance
Reported by ~50% of study participants Gut axis (constipation, indigestion, diarrhoea) Sleep (difficulty to wake, sleeping during day)
New allergies Sighing breaths
Arrhythmia Confusion
Smell sensitivity
Reported by ≤10% of study participants Migraine headache Sensitivity to touch
High heart rate upright Pain frequency
  1. Epworth sleep scale: 0–10 (normal daytime sleepiness): 11–15 (excessive daytime sleepiness): 16–24 (severe daytime sleepiness)
  2. Height was significantly greater for the healthy control cohort (p = 0.002, Mann–Whitney U). Diastolic blood pressure and pulse rate were significantly elevated for CFS/ME (p < 0.05, Mann–Whitney U). CFS/ME (n = 40 to 43); Healthy Controls (n = 7 to 17)
  3. BMI body mass index, bpm beats per minute